| C80405 | A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab or Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (1308)-
Eligibility: click to view information
***Additional Forms Needed at Time of Consent see sectino 5.7***
**check test schedule for pre-study reqs**
STUDY DRUG: Commercially available- Oxaliplatin pg 52; 5 FU pg 54; Leucovorin pg 54; Irinotecan pg 55, Bevacizumab pg 56--PROVIDED- Cetuximab pg 58
1) Histo or cyto documented locally advanced metastatic Colon CA
2) Intent of tx must be indicated at enrollment
3) No prior tx for diagnosis
4) no significant history of bleeding or GI perforation
- HIPAA Forms: 80405 HIPAA
- Consent Forms: 80405 Consent
|
